AbbVie price drops — what’s behind today’s move

Traders Union
All News
Financial News
Abbvie slides 7.54% today

Highlights

AbbVie reported Q4 revenue of $16.62 billion, beating analyst estimates, with full-year adjusted diluted EPS of $10.00, down 1.2% year-on-year.
The company projects robust adjusted profit per share in 2026, driven by newer immunology drugs and a modestly slower Humira sales decline.
ABBV closed at $208.61, just below its MA-200 ($208.93) and well under short- and medium-term moving averages, highlighting current technical weakness despite low downside probability.

Revenue beat and growth outlook bolster sentiment despite earnings dip

AbbVie reported fourth-quarter revenue of $16.62 billion, exceeding analyst estimates, and delivered full-year adjusted diluted EPS of $10.00, down 1.2% year-on-year. The company projects strong adjusted annual profit per share in 2026, supported by growth in newer immunology medicines and a smaller decline in Humira sales. Regulatory filings to expand Rinvoq's indications and progress in oncology and aesthetics, including Botox, further underscore the firm's operational momentum.

Anton Kharitonov, expert at Traders Union, highlights AbbVie's technical and fundamental fragility. He notes that price action below both MA-20 and MA-50, along with a decisive gap down, signals persistent bearish sentiment. Despite revenue beating expectations, adjusted EPS continued to decline, and Humira’s slowdown remains a significant threat. The weak ADX and conflicted momentum indicators expose the stock to further selling if negative news arises. Kharitonov states: "Given the fragile technicals and unresolved structural risks, ABBV may struggle to regain buyer conviction in the near term."

Viktoras Karapetjanc, expert at Traders Union, sees strong opportunity for a rebound in AbbVie. He stresses constructive revenue results and robust guidance for 2026 as drivers of positive sentiment. Despite a short-lived selloff, the bullish structure remains intact with new immunology drugs and pipeline strength supporting upside. Karapetjanc adds: "With projected growth in key franchises, investors should anticipate a recovery and further upside this quarter."

Jainam Mehta, market strategist, observes tactical uncertainty in AbbVie’s setup. He notes that the gap down presents a potential reversal zone if bullish momentum returns, but warns that mixed oscillators warrant caution. Mehta suggests traders track support near $208.93 for possible contrarian entries. He concludes: "A fast snapback above resistance or a clean breakdown will define the next directional trade."

Daily sell bias intensifies amid mixed momentum and gap-down volatility

Momentum signals are conflicted — MACD signals a strong daily sell bias even as ADX remains weak, signaling lack of trend strength. Stoch RSI and CCI point to overbought conditions, while BBP indicates a recent dominance of buyers, but sellers have taken control intraday. ABBV opened sharply lower today, creating a notable gap down from $225.63 to $210.29 and sliding further to $208.61 near the session low, with persistent selling and heightened volatility. This intraday behavior confirms short-term weakness and continued downside momentum, despite lingering overbought signals and mixed oscillators.

Previously it was reported that AbbVie remains in a long-term uptrend, despite trading below its short- and medium-term moving averages and facing ongoing short-term consolidation. Momentum indicators are mixed, with weekly RSI reflecting a neutral-to-weak downside bias as the stock continues to range between nearby support at $218 and resistance near $223.50–$225.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.